Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen
May 12, 2020
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Chuikyo OKs Special Mixed Care Scheme for Veklury
May 11, 2020
- Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
- Gilead Japan Expected to Offer Remdesivir for Free for Now
May 7, 2020
- Japan to Test Ivermectin for COVID-19: Prime Minister
May 7, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Eyes Manufacturing Repatriation for 3 APIs: Extra Budget
May 1, 2020
- Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- Japan to Quickly Utilize “Special Approval” Scheme for Remdesivir after It’s OK’ed Overseas: Minister
April 30, 2020
- Antigen Test for New Coronavirus Filed in Japan: Minister
April 28, 2020
- Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
- Japan Starts Assessing Performance of Antibody Test Kits: Minister
April 27, 2020
- Drug Makers Should Join in “Concerted National Effort” to Propel Regulatory Harmonization in Asia: Ex-PMDA Chair
April 27, 2020
- Japan Moving to Thwart Foreign Takeover of Drug, Medical Devices Makers
April 24, 2020
- In a First, Chuikyo to Be Streamed Live amid COVID-19 Outbreak
April 23, 2020
- Japan to Make Drug Review Time as Short as Possible for COVID-19: Minister
April 22, 2020
- Novartis’ Entresto, Mayzent Up for MHLW Panel Review in Round Robin Method
April 20, 2020
- Japan Declares Nationwide State of Emergency
April 17, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…